AZD9291 , 99% , 1421373-65-0

CAS NO.：1421373-65-0

Empirical Formula: C28H33N7O2

Molecular Weight: 499.61

MDL number: MFCD27988062

EINECS: 629-848-5

PRODUCT Properties

• Melting point: >188oC (dec.)
• Density: 1.19±0.1 g/cm3(Predicted)
• storage temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• solubility: DMSO (Slightly, Heated), Methanol (Slightly, Heated)
• pka: 12.68±0.70(Predicted)
• form: Solid
• color: Pale Yellow to Beige
• CAS DataBase Reference: 1421373-65-0

Description and Uses

AZD-9291 (Mesylate), also known as Osimertinib, belongs to a third-generation EGFR (epidermal growth factor receptor) inhibitor. It can be used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in case when the cancer cells carry specific mutations (such as T790M) in the epidermal growth factor receptor. It takes effect through directly binding to the certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions) that are frequently found in NSCLC, further causing poor prognosis for late-stage disease. Since it spares wild type EGFR during therapy, it has only limited toxicity.

AZD 9291 is an irreversible inhibitor of epidermal growth factor receptor (EGFR) sensitizing and T790M resistance mutations (IC50s = 15-17 nM) while sparing the wild-type form of the receptor (IC50 = 480 nM). It binds the related IGF1R and hERG receptors with significantly reduced potency (IC50s = 2.9 and 16.2 μM, respectively). AZD 9291 has been shown to inhibit tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg and has been tested clinically in patients with advanced EGFR mutant non-small-cell lung cancer.[Cayman Chemical]

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319-H335
• Precautionary statements: P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P321-P362+P364-P332+P313-P337+P313-P403+P233-P405-P501
• HS Code: 29339900